Studio Multicentrics Su Patogeni Delle Vie Urinarie Isolati Da Pazienti Ambulatoriali

Bauemfein A. : An evaluation of the activity of cephalosporin against Pseudomonas aeruginosa. J. Antimicrob. Chemother., 8; suppl. B, 111–117 (1981).

Bint A. J. , fi Yeoman P. , Kilburn P. , Anderson R. , Stansfield E. : The in vitro activity of ceftazidime compared with that of other cephalosporins. J. Antimicrob. Chemother., 8; suppl. B, 47–51 (1981).

Croww A. W. , Bartlett K. H. : Comparative in vitro activity of ceftazidime (GR 20263) and other betalactamase stable cephalosporins against anaerobic bacteria. J. Antimicrob. Chemother., 8; suppl. B, 331–337 (1981).

Grunenberg R. N. : The bacteriology of urinary tract infection: does it matter? Proc. Roy. Soc. Med., 65; 514 (1972).

Harper P. B. : The in vitro activity of ceftazidime. J. Antimicrob. Chemother., 8; 5–13 (1981).

Knothe H. , Dette G. A. : The in vitro activity of ceftazidime against clinically important pathogens. J. Antimicrob. Chemother., 8; suppl. B, 33–41 (1981).

Lennette E. H. , Spaulding E. H. , Truant J. P. : Manual of clinical Microbiology, 2nd ed. American Society of Microbiology, Bethesda 1976.

Stamey T. E. : Pathogenesis and treatment of urinary infections, p. 1–51. Williams & Wilkins, Baltimore London 1980.

Thornsberry C. , Anhalt J. P. , Washingtin J. A. , McCarthy L. R. , Schoenknect F. D. , Sherris J. , Spencer H. I. : Clinical laboratory evaluation of the Abbot MS-2 automated antimicrobial susceptibility testing system: report of a collaborative study. J. clinical Microb., 12; 375–390 (1980).

Williams R. J. , Williams J. D. : The cephalosporin group of antibiotics. In: Antibiotics and Chemotherapy - Current topics, p. 63–113. Gruneberg R. N. (ed.). MTP Press, Lancaster 1980.

Wilkinson I. A. , Gentry L. O. : In vitro comparison of ceftazidime and nine other antimicrobial agents against strains of Gram-negative bacteria. J. Antimicrob. Chemother., 8; 53–56 (1981).

Wise R. , Andrews J. M. , Bedford K. A. : Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicr. Agents & Chemoth., 17; 884–889 (1980).